| Name | Title | Contact Details |
|---|
Exela Pharma Sciences is a Lenoir, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Infinity Pharmaceuticals is an innovative cancer drug discovery and development company that leverages its strength in small molecule drug technologies to bring important new medicines to patients.
National Vitamin Company formulates, manufactures, tests, and distributes OTC Pharmaceuticals, Dietary Supplements, and Personal Care products for the global marketplace. The Quality Unit will define, devise, test, and enforce material standards and
Innocrin discovers and develops novel, best-in-class oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of castration-resistant prostate cancer (CRPC). VT-464 and structurally-related classes of CYP17 inhibitors are wholly owned by Innocrin. CYP17 lyase inhibitors may also have high commercial potential for the treatment of breast cancer as well as non-oncologic syndromes that are due to hormonal excess including endometriosis, polycystic ovary syndrome and congenital adrenal hyperplasia.
Satsuma Pharmaceuticals is focused on developing best-in-class products to address the unmet needs of migraine sufferers.